# Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

> **NCT05946551** · PHASE3 · TERMINATED · sponsor: **Emory University** · enrollment: 5 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** Cetirizine
- **DRUG:** Famotidine
- **DRUG:** Cetirizine Placebo
- **DRUG:** Famotidine Placebo

## Key facts

- **NCT ID:** NCT05946551
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-03-08
- **Primary completion:** 2024-06-24
- **Final completion:** 2024-06-24
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study was terminated due to lack of funding.
- **Last updated:** 2025-07-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05946551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05946551, "Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05946551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*